Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA-Reference-Cited by-同舟云学术

Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA

Published:2024-07 Issue:7 Volume:11 Page:e510-e520
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Khan Mohammad K,Nasti Tahseen H,Qian Joshua Y,Kleber Troy J,Switchenko Jeffrey M,Kaufman Jonathan L,Nooka Ajay J,Dhodapkar Madhav V,Buchwald Zachary S,Obiekwe Daby,Lonial Sagar,Ahmed Rafi

Publisher

Elsevier BV

Reference29 articles.

1. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study;Kumar;Leukemia,2017

2. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD;Usmani;Oncologist,2016

3. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013;Ribrag;Br J Haematol,2019

4. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial;Mateos;Lancet Haematol,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to Lancet Haematol 2024; 11: e510–20;The Lancet Haematology;2024-08

2. The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. Pembrolizumab plus single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma;The Lancet Haematology;2024-07